Agios_Pharmaceuticals
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.[3] The company was founded in 2008 (or 2007)[4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[2][5] The company tendered an initial public offering in July 2013.[6]: Table 1
| Company type | Public |
|---|---|
| Nasdaq: AGIO Russell 1000 Component | |
| Industry | Pharmaceuticals |
| Founded | 2008; 16 years ago (2008) |
| Headquarters | , United States |
Key people | Brian Goff (CEO) |
| Revenue |  $118 Million(2019)[1] |
Number of employees | 536 |
| Website | agios |
| Footnotes / references Foundation[2] | |
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.[4]
In May 2016, the company announced it would launch partnership with Celgene,[7] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.[8]
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug, Enasidenib[9]
In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or R/R AML with an IDH1 mutation.[10]
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.[11]
In April 2022, FDA approved PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for hemolytic anemia in adults with Pyruvate Kinase Deficiency.[12]
As of August 2022[update], Agios' CEO is Brian Goff.[13]
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.[4][6]
- Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
- Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.
- "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
- Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71.
- Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
- "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
- "Agios Announces Pricing of $256 Million Public Offering of Common Stock". www.nasdaq.com. Retrieved 2020-03-12.
- "Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency". Agios. Cambridge, MA. 17 February 2022. Retrieved 24 April 2023.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |